PubMed · 11883697
Technology evaluation: BL22, NCI.
Abstract
BL22 (RFB4(dsFv)-PE38) is a recombinant Pseudomonas exotoxin-based immunotoxin under development by the National Cancer Institute for the treatment of B-cell malignancies. It is composed of the disulfide-stabilized Fv portion of the anti-CD22 antibody RFB4 genetically fused to a truncated form of Pseudomonas exotoxin A. It has entered phase I trials for the treatment of B-cell lymphoma.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Stefan Barth. 2002. Technology evaluation: BL22, NCI.. https://pubmed.ncbi.nlm.nih.gov/11883697/
Cite the original work for its findings. Save a collection to share your selection of sources.